1、The GLP1 EffectStrategic implications for the MedTech industryStrategy&|The GLP1 Effect2ContactsGermanyDr.Till Giese,Partner,Strategy&Germany+49-1515-5932-Iryna Scheurlen,Director,Strategy&Germany+49-171-9419-Oliver Dolny,Senior Manager,Strategy&Germany+49-1511-4455-About the authorsDr.Till Giese is

2、 a Partner at Strategy&Germany,based in Hamburg.He advises international clients from the pharmaceutical,MedTech,and healthcare industries.With more than 18 years of industry experience,he specializes in strategy development and implementation,large scale transformations,innovation,digitalization an

3、d operational excellence.With this,he aims to lead clients to sustainable growth.Oliver Dolny is a Senior Manager at Strategy&Germany,based in Munich.He advises clients in the MedTech and pharmaceutical industries on strategy development,large-scale transformation,and operating model design.With sev

4、eral years of consulting experience and industry exposure,he supports organizations in addressing structural challenges and enabling long-term growth.Ellen Zimmermann advises clients on strategy and digital transformation for Strategy&with a focus on Pharma and Life Sciences.She has worked with orga

5、nizations across multiple countries on commercial strategy,go-to-market strategy,and business model innovation.Based in Munich,she is an Associate at Strategy&Germany.Kirsten Burmeister,Manager at Strategy&Germany,also contributed to thisreport.Strategy&|The GLP1 Effect3Glucagon-like-Peptide-1(GLP-1

6、)has attracted enormous attention over recent years due to its effectiveness in aiding weight loss,and in treating and inducing remission of type 2 diabetes mellitus.Further emerging use cases for GLP-1,for example in the treatment of chronic kidney disease and in certain types of addiction,have onl